<?xml version="1.0" encoding="UTF-8"?>
<p>The Traditional Chinese Medicines (TCM) were highly considered by Government of China in their campaign against COVID‐19. To evaluate the safety and efficacy of treatments for COVID‐19 patients, China launched more than 300 clinical trials on March 1, 2020. Among the total treatments, 16.5% (50 trials) were linked to the use TCM where 4.6% (14 cases) were linked to examine the combine use of Western medicine and TCM. Among the trials of TCM, 22 (7.3%) were launched to evaluate the efficacy of self‐made herbal preparations including QingYi‐4, Xin Guan‐1 Formula and Xin Guan‐2 Formula. The commercially available TCM products like Lian Hua Qing Wen capsules and Tan Re Qing injections were also studied in 14 (4.6%) trials (Yang et al., 
 <xref rid="ptr6786-bib-0083" ref-type="ref">2020</xref>). The therapeutic effects of TCM herbal remedies for the treatment of SARS coronavirus have also been published (Luo et al., 
 <xref rid="ptr6786-bib-0055" ref-type="ref">2020</xref>; Yang et al., 
 <xref rid="ptr6786-bib-0083" ref-type="ref">2020</xref>). Regardless the complex formulation of TCM, herbs such as 
 <italic>Scutellaria baicalensis</italic> and 
 <italic>Glycyrrhiza glabra</italic> were available in tested TCM preparations. The extracted baicalin and glycyrrhizin compounds from the mentioned herbs have in vitro evidences of anticoronaviral activity (Chen et al., 
 <xref rid="ptr6786-bib-0018" ref-type="ref">2004</xref>). The anticoronavirus TCM remedies included plants such as 
 <italic>Lonicerae japonicae, Saposhnikovia divaricate</italic>, 
 <italic>Forsythia Vahl</italic>, and 
 <italic>Atractylodis macrocephalae</italic> (Luo et al., 
 <xref rid="ptr6786-bib-0055" ref-type="ref">2020</xref>). This could identify new directions for future research.
</p>
